ArticleJournal of health economics2020
Health technology assessment with risk aversion in health.
Article in Journal of health economics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- The value of timely treatment with anti-amyloid therapy for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The economic burden of functional neurological disorder.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- The social value of lecanemab for patients with early Alzheimer's disease in Japan.Journal of Alzheimer's disease : JAD · 2026Article
- Risk attitudes and value of hope: survey results from Japanese hematologists and oncologists treating patients with diffuse large B-cell lymphoma.Scientific reports · 2026Article
- Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer's Disease: A U.S. Cost Comparison Model.Neurology and therapy · 2025Article
- Handling uncertainty in cost-effectiveness analysis in dental medicine: a systematic review with a focus on affordability and risk-aversion.Cost effectiveness and resource allocation : C/E · 2025Review
- Health Risk and the Value of Life.Journal of public economics · 2025Article
- Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments.PharmacoEconomics · 2025Article
- Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.Neurology and therapy · 2024Article
- A principled approach to non-discrimination in cost-effectiveness.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Incorporating Real Option Value in Valuing Innovation: A Way Forward.PharmacoEconomics · 2024Article
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.Forum for health economics & policy · 2024Article
- Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.Neurology and therapy · 2023Article
- Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.Neurology and therapy · 2023Article
- A review of HTA guidelines on societal and novel value elements.International journal of technology assessment in health care · 2023Review
- Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study.PharmacoEconomics · 2023Article
- Article
- Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer.Frontiers in oncology · 2023Review
- Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Article
- Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.PharmacoEconomics · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Standard cost-effectiveness models compare incremental cost increases to incremental average gains in health, commonly expressed in Quality-Adjusted Life Years (QALYs). Our research generalizes earlier models in several ways. We introduce risk aversion in Quality of Life (QoL), which leads to "willingness-to-pay" thresholds that rise with illness severity, potentially by an order of magnitude. Unlike traditional CEA analyses, which discriminate against persons with disabilities, our analysis implies that the marginal value of improving QoL rises for disabled individuals. Our model can also value the uncertain benefits of medical interventions by employing well-established analytic methods from finance. Finally, we show that traditional QALYs no longer serve as a single index of health, when consumers are risk-averse. To address this problem, we derive a generalized single-index of health outcomes-the Generalized Risk-Adjusted QALY (GRA-QALY). Earlier models of CEA that abstract from risk-aversion nest as special cases of our more general model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.